Published in Surgery Litigation and Law Weekly, August 24th, 2007
Study 1: "We previously reported on an improvement in survival and quality of life in chemotherapy-naive patients with advanced non-small-cell lung cancer and low performance status (PS) treated with a combination of biotherapeutical agents and cyclophosphamide. In this study, we assessed the survival, clinical status, and toxicity of this multidrug regimen in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low PS," scientists in Verona, Italy report.
"Patients with stage IIIB or IV lung adenocarcinoma, who had progressed after prior standard...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.